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Inflammation is an important physiological host defense mechanism that is subverted in multiple chronic diseases. 
During atherogenesis, it is thought that an innate immune 
response against factors perceived as pathogens within the 
vessel wall drives inflammation and initiates plaque growth. 
Suggested factors include modified lipids, cholesterol and 
calcium crystals,1 and danger signals released from dying and 
necrotic cells.2 These can cause activation of endothelial cells 
(ECs) and recruitment of leukocytes into the subendothelial 
space.3 Perpetual chronic inflammation results through a poorly 
understood milieu of cyclic cytokine cascades, activation, 
recruitment, proliferation and death, and driving atherogenesis. 
This model is generally supported by mice deficient in the rel-
evant cytokines, receptors, or adhesion molecules, which show 
modulation of atherosclerosis.4 However, much less is known 
about the role endogenous vessel wall cells play in these pro-
cesses, and importantly whether they can initiate inflammation.
Most plaques consist of a fibrous cap, composed of vascu-
lar smooth muscle cells (VSMCs), collagen, and extracellular 
matrix that separate a necrotic core from the lumen. In addi-
tion, macrophages and T-lymphocytes are present, particu-
larly in the shoulder regions of the plaque. Plaque stability 
is determined in part by the number of VSMCs and the struc-
tural matrix they synthesize.5 Myocardial infarction occurs 
when fibrous cap rupture exposes the underlying necrotic core 
and matrix, causing thrombosis and vessel occlusion. Many 
ruptured plaques are clinically silent, suggesting repair and 
healing commonly occurs. VSMC proliferation and matrix 
synthesis are crucial to the repair process. However, unstable 
mature plaques show low levels of VSMC proliferation and 
clear evidence of VSMC senescence.6 Similarly, restenotic 
neointimas also contain senescent VSMCs.7 Senescence is a 
protective mechanism engaged in response to excessive stress 
that induces permanent cell cycle arrest to prevent transmis-
sion of defects to the next generation, particularly to stop 
malignant transformation. Senescence can occur after repeated 
cell division (replicative senescence) or be induced by mito-
chondrial deterioration, DNA damage or oxidative stress—all 
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Objective—Vascular smooth muscle cells (VSMCs) that become senescent are both present within atherosclerotic plaques 
and thought to be important to the disease process. However, senescent VSMCs are generally considered to only 
contribute through inaction, with failure to proliferate resulting in VSMC- and collagen-poor unstable fibrous caps. 
Whether senescent VSMCs can actively contribute to atherogenic processes, such as inflammation, is unknown.
Approach and Results—We find that senescent human VSMCs develop a proinflammatory state known as a senescence-
associated secretory phenotype. Senescent human VSMCs release high levels of multiple cytokines and chemokines 
driven by secreted interleukin-1α acting in an autocrine manner. Consequently, the VSMC senescence-associated 
secretory phenotype promotes chemotaxis of mononuclear cells in vitro and in vivo. In addition, senescent VSMCs 
release active matrix metalloproteinase-9, secrete less collagen, upregulate multiple inflammasome components, and 
prime adjacent endothelial cells and VSMCs to a proadhesive and proinflammatory state. Importantly, maintaining the 
senescence-associated secretory phenotype places a large metabolic burden on senescent VSMCs, such that they can be 
selectively killed by inhibiting glucose utilization.
Conclusions—Senescent VSMCs may actively contribute toward the chronic inflammation associated with atherosclerosis 
through the interleukin-1α–driven senescence-associated secretory phenotype and the priming of adjacent cells 
to a proatherosclerotic state. These data also suggest that inhibition of this potentially important source of chronic 
inflammation in atherosclerosis requires blockade of interleukin-1α and not interleukin-1β.  (Arterioscler Thromb Vasc 
Biol. 2015;35:1963-1974. DOI: 10.1161/ATVBAHA.115.305896.)
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processes VSMCs are exposed to within plaques. Because 
VSMC proliferation and matrix production are required to 
stabilize the fibrous cap, senescence is suggested to promote 
plaque instability. Thus, senescent VSMCs are generally con-
sidered to be bystanders that only contribute to atherogenesis 
through inaction.
On the contrary, many senescent tumor cells develop 
altered secretory activities, known as a senescence-associated 
secretory phenotype (SASP). SASPs contain proinflammatory 
cytokines (eg, interleukin-6 [IL-6], IL-1) and chemokines (eg, 
IL-8, GROα), growth factors (eg, granulocyte-colony stimu-
lating factor [G-CSF], basic fibroblast growth factor [bFGF]), 
proteases (eg, matrix metalloproteinases [MMPs], plaminogen 
activator inhibitor-1 [PAI-1]), but never anti-inflammatory fac-
tors.8 Thus, the mitostatic effect of senescence is counterbal-
anced by the effects of the SASP on the local milieu. In many 
cases, the SASP is driven by cell surface IL-1α9 and secreted 
IL-1β,10 which both bind the IL-1 receptor type 1 (IL-1R1) and 
induce identical signaling. IL-1–mediated effects, such as cyto-
kine production, EC/macrophage activation, increased adhesion 
molecules, and increased vascular permeability11 are all impor-
tant during atherogenesis. Indeed, atherosclerosis in mice is 
increased with more IL-1 signaling or decreased with less.12–15
We find that senescent VSMCs establish a proinflamma-
tory SASP, characterized by chronic secretion of multiple pro-
atherogenic cytokines and active MMP9, but downregulation 
of collagen. This SASP acts as a potent stimulus for the che-
motaxis of mononuclear cells in vitro and in vivo. Senescent 
VSMCs upregulate multiple inflammasome components with 
the autocrine secretion of IL-1α solely responsible for driving 
the SASP. Furthermore, IL-1α also primes adjacent VSMCs 
and ECs to a proinflammatory and proadhesive state. These 
data imply that senescent VSMCs may actively drive chronic 
inflammation and matrix destruction in plaques.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Senescent VSMCs Are a Feature of Advanced 
Plaques, Which Can Be Modeled In Vitro
Aging is the dominant risk factor for atherosclerosis, with 
senescent cells a key feature of aged tissues in humans. 
Although there are no completely specific markers for senes-
cent cells, many cell types express a pH-labile enzyme called 
senescence-associated β-galactosidase (SAβG) when they 
undergo senescence because of multiple stimuli. Advanced 
human atherosclerotic plaques expressed SAβG-positive cells 
in the intima, most marked in the fibrous cap (Figure 1A; 
Figure I in the online-only Data Supplement). Double labeling 
revealed ≈70% of these cells express α-smooth muscle actin 
(Figure 1A), indicative of VSMC origin. In addition, senescent 
cells are also observed in peripheral regions overlying less 
mature plaques (Figure I in the online-only Data Supplement).
Senescence can be induced by multiple stimuli, for 
example, replicative exhaustion, DNA damage, and activa-
tion of oncogenes,8 and often occurs because of the com-
bined effect of these factors. VSMCs undergo replicative 
senescence after 12 to 20 population doublings, but this is 
greatly accelerated by DNA damage.16 Thus, we studied 
both replicative and DNA damage–induced senescence in 
VSMCs. Human VSMCs derived from disease-free aorta 
were cultured until senescent or pulsed with the DNA 
damaging agent bleomycin. Both VSMC cultures showed 
an enlarged flattened morphology and SAβG activity in 
≥80% of cells (Figure 1B and 1C). Bleomycin-treated 
VSMCs showed both a dose and time-dependent increase 
in SAβG activity with 50 µg/mL of bleomycin giving ≈80% 
positive cells by day 11 (Figure II in the online-only Data 
Supplement), but without the cell death seen with higher 
doses (Figure III in the online-only Data Supplement). 
Importantly, both senescent cultures showed <5% prolif-
eration, as evidenced by BrdU (5-bromo-2´-deoxyuridine) 
incorporation (Figure 1D and 1E; Figure IV in the online-
only Data Supplement), and persistent unrepaired DNA 
damage, as evidenced by increased nuclear foci of γ-H2AX 
(Figure 1F; Figure V in the online-only Data Supplement), 
which colocalized with SAβG-positive VSMCs (Figure VI 
in the online-only Data Supplement). Once established, 
senescent cells were remarkably stable showing low rates of 
cell loss (Figure VII in the online-only Data Supplement), 
with cultures of replicatively senescent cells stable in cul-
ture for >180 days (Figure VII in the online-only Data 
Supplement). This combination of SAβG staining, flattened 
morphology, low proliferation, and persistent DNA damage 
are features of senescent cultures in multiple cell types,8 
confirming our models of VSMC senescence.
Senescent VSMCs Secrete Multiple Inflammatory 
Cytokines in an IL-1α–Dependent Manner
A key feature of senescence in many cell types is a SASP, 
whereby a large range of cytokines and chemokines are per-
sistently secreted.8 Human VSMC senescence was associated 
with secretion of high levels of the classic SASP cytokine IL-6 
and chemokine IL-8 in both replicatively senescent (Figure 2A) 
and induced senescent (Figure 2B) VSMC cultures. Extended 
profiling by cytometric bead array (Figure VIII in the online-
only Data Supplement) and antibody array (Figure IX in the 
online-only Data Supplement) revealed that senescent VSMCs 
also secrete increased levels of the powerful leukocyte chemoat-
tractants monocyte chemoattractant protein-1 (MCP-1), macro-
phage inflammatory protein-1α (MIP-1α)/CCL3, and MIP-1β/
CCL4, and reduced levels of RANTES and the IL-1 antagonist 
soluble IL-1R2. As IL6, IL8, and MCP1 are IL-1 responsive 
genes, we investigated whether IL-1 induces the SASP in senes-
cent VSMCs. Specific blockade of IL-1α prevented the SASP, 
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with significant reduction of both IL-6 and IL-8 in both induced 
(Figure 2C) and replicatively senescent cultures (Figure 2D), 
whereas blockade of IL-1β did not (Figure 2E and 2F). Together 
this suggests that the SASP in senescent VSMC cultures is 
driven by IL-1α and that induced and replicative senescence 
share common features and SASP components in VSMCs. As 
replicative senescence requires long-term culture and cannot 
provide passage-matched control cells, we investigated specific 
effects of the SASP factors with induced VSMC senescence.
Physiological Secretion of IL-1α by Senescent 
VSMCs Drives the SASP in an Autocrine Manner
IL-1α has been varyingly reported to be exclusively cytoplas-
mic, physiologically secreted by inflammasome-dependent17,18 
or -independent19 mechanisms, and also to exist as a cell mem-
brane–tethered mature form.20 In addition, IL-1α is a key dan-
ger signal that induces inflammation on release from necrotic 
cells.2,21,22 We therefore determined whether the IL-1α–
dependent SASP in senescent VSMC cultures was because of 
secretion, a membrane-tethered form, or potentially release 
from necrotic cells. Lactate dehydrogenase as a marker of 
necrosis was similar in the conditioned media from control 
and senescent VSMCs (Figure 3A). In addition, the delib-
erate spiking of control and senescent VSMC cultures with 
necrotic VSMCs at typically observed levels did not increase 
IL-6 release (Figure 3B). Together these data imply that the 
IL-1α–dependent SASP is not because of increased leakage 
from necrotic cells in senescent VSMC cultures. Previous 
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Figure 1. Vascular smooth muscle cell (VSMC) senescence, which occurs in mature plaques, can be modeled in vitro. A, Human carotid 
plaque stained for senescence with senescence-associated β-galactosidase (SABG; blue) and VSMCs with α-smooth muscle actin 
(αSMA; brown), as indicated. Most SABG +ve cells are in the fibrous cap region, whereas dual staining shows the majority of senescent 
cells to be VSMCs (arrows), although some senescent cells with a VSMC-like morphology do not stain for αSMA (arrow heads). B–F, 
Replicative and induced senescent VSMCs were stained and enumerated for SABG (B and C) and BrdU (5-bromo-2´-deoxyuridine; D and 
E) +ve cells, or stained for persistent DNA damage with γH2AX (F). Data represent mean±SD, representative of n=≥3. Scale bars repre-
sent 200 mm (low power) and 50 mm (high power).
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work that reported a role for IL-1α in the maintenance of 
SASPs suggested it to be exclusively mediated by cell-surface 
IL-1α.9 We could not find IL-1α on the surface of senescent 
VSMCs by flow cytometry, in contrast to lipopolysaccharide-
activated THP-1 cells used as a positive control (Figure 3C). 
In contrast, the conditioned media from senescent VSMCs 
contained active IL-1α, as evidenced by the specific reduction 
in IL-1–dependent IL-2 production with an IL-1α neutralizing 
antibody (Figure 3D) and by ELISA (Figure X in the online-
only Data Supplement).
We next sought to determine whether IL-1α is a proximal 
initiator of the VSMC SASP or acts more as a distal effector of 
the factors released. Senescent VSMCs cultured continuously 
with IL-1α blockade released basal levels of IL-6 (Figure 3E). 
However, short-term release (6 hours) of IL-1α blockade 
resulted in the immediate reestablishment of the SASP, as 
evidenced by the rapid secretion of IL-6 into the conditioned 
media (Figure 3E). This suggests that although IL-1α drives 
the production of SASP factors, its inhibition does not phe-
notypically alter a senescent cell, implying IL-1α is the api-
cal downstream effector of SASPs rather than an upstream 
inducer of senescence.
Senescent VSMCs Induce Chemotaxis, 
Secrete Active MMP-9, and Upregulate 
Inflammasome Components
Our data suggest that senescent VSMCs actively secrete 
IL-1α that drives the SASP in an autocrine/paracrine fash-
ion. Furthermore, in contrast to senescent cell types that have 
surface IL-1α that is likely to only affect neighboring cells, 
IL-1α secreted from senescent VSMCs might stimulate more 
distant cells. A key feature and driver of atherogenesis is the 
continual recruitment of monocytes from the circulation; 
we therefore investigated whether senescent human VSMCs 
could induce chemotaxis of mononuclear cells. THP-1 cell 
migration was increased 8-fold toward senescent than control 
VSMCs (Figure 4A). Migration was inhibited significantly by 
treatment of the senescent VSMCs with an IL-1α neutralizing 
antibody before the assay or an MCP-1 neutralizing antibody 
added during the chemotaxis assay (Figure 4A). Blocking IL-8 
during the assay did not reduce recruitment. This indicates 
that IL-1α drives production of chemoattractants from senes-
cent VSMCs and that the main chemoattractant of monocytic 
cells within the SASP is MCP-1. To confirm that senescent 
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Figure 2. Senescent vascular smooth muscle 
cells (VSMCs) secrete cytokines and chemokines 
in an interleukin-1α (IL-1α)–dependent manner. 
Cytokine and chemokine content of conditioned 
media from control, replicative (A) and induced 
(B) senescent VSMC cultures measured by 
ELISA. IL-6 and IL-8 content of conditioned 
media from control and senescent VSMCs 
incubated ±neutralizing IL-1α (C and D) or IL-1β 
antibodies (E and F). Data represent mean±SEM 
of n=5 (A–C, E, and F), 3 (D); *P≤0.05, **P≤0.02, 
and ***P≤0.005. NS indicates not significant.
Gardner et al  Senescent VSMCs Drive Inflammation via IL-1α  1967
injected live VSMCs into the peritoneal cavity of mice. Again, 
senescent VSMCs caused significantly more recruitment of 
monocyte/macrophages and lymphocytes, but not neutrophils, 
compared with control VSMCs (Figure 4B; Figure XI in the 
online-only Data Supplement).
We also examined the effect of VSMC senescence on other 
IL-1–induced genes, and the effect of senescence on expres-
sion of inflammasome components that maybe required for 
IL-1α secretion. MMP plays a key role in degrading the struc-
tural matrix that strengthens the fibrous cap and are secreted 
by some senescent tumor cells. Using gelatin zymography, 
we find that control VSMCs secrete pro-MMP2. In con-
trast, senescent VSMCs release pro-MMP2, pro-MMP9, and 
active MMP9 (Figure 4C). IL-1–primed control VSMCs did 
not secrete active MMP9, suggesting this process to not only 
be IL-1–dependent in VSMCs. As VSMC-produced struc-
tural matrix maintains the fibrous cap, we assessed collagen 
production and found senescent VSMCs generate signifi-
cantly less than control cells (Figure 4D). Senescent VSMCs 
also showed polarization between low and high α-smooth 
muscle actin expression (Figure XII in the online-only Data 
Supplement). Secretion of IL-1α has been suggested to 
require active caspase-1,17,18 and thus assembly and activation 
of inflammasomes. Using quantitative polymerase chain reac-
tion, we profiled control and senescent VSMCs for levels of 
inflammasome components and associated factors. Senescent 
VSMCs contained significantly increased levels of transcripts 
for IL-1β, IL-1α, NLR family, CARD domain containing 
4 (NLRC4), nucleotide-binding oligomerization domain-
containing protein 2 (NOD2), and NACHT, LRR, and PYD 
domains-containing protein 1 (NLRP1) (Figure 4E), indicative 
of a shift toward a more proinflammasome phenotype.
VSMC SASP Primes Adjacent Control 
Cells to a Proinflammatory State
As senescent VSMCs secrete IL-1α, and the classic inflam-
masome priming toll-like receptor ligands (eg, lipopolysac-
charide) induce equivalent downstream signaling as IL-1, 
we investigated whether IL-1α could also prime local con-
trol VSMCs or macrophages to a proinflammasome phe-
notype. Treatment of control VSMCs with IL-1α led to an 
upregulation of inflammasome components comparable with 
that seen in senescent VSMCs (Figure XIII in the online-
only Data Supplement), although macrophages showed no 
response to IL-1α (not shown). Importantly, given that the 
SASP is a complex mixture of cytokines, we determined 
whether conditioned media from senescent VSMCs could 
activate normal VSMCs and ECs. As this conditioned media 
already contains SASP factors, we treated target cells with 
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Figure 3. Secretion of interleukin-1α (IL-1α) by senescent vascular smooth muscle cells (VSMCs) drives the senescence-associated 
secretory phenotype in an autocrine manner. A, Lactate dehydrogenase (LDH) activity in conditioned media (CM) from control and senes-
cent VSMCs, lysed cells (+ve) or buffer only (−ve). B, IL-6 content of conditioned media from control and senescent VSMCs incubated 
with the indicated % of necrotic control and senescent VSMCs. C, Flow cytometry analysis of senescent VSMCs and lipopolysaccharide 
(LPS)-treated THP-1 cells stained with isotype control-FITC (fluorescein-5-isothiocyanate; red) or anti-IL-1α−FITC (blue). D, IL-1–de-
pendent IL-2 production by EL4 cells incubated with senescent VSMC conditioned media (CM), ±neutralizing IL-1α pAb. E, IL-6 content 
of media conditioned by senescent VSMCs incubated ±IL-1α pAb as a pretreatment or during supernatant collection. Data represent 
mean±SEM of n=3 (B and E), 4 (D); *P≤0.05, **P≤0.02, and ***P≤0.005.
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within cell lysates after exposure to conditioned media 
from control or senescent VSMCs. Conditioned media 
from senescent VSMCs led to IL-1α–dependent produc-
tion of IL-6, IL-8 (Figure 5A and 5B), and MCP-1 (Figures 
XIV and XV in the online-only Data Supplement) in both 
VSMCs and ECs, whereas media from control VSMCs 
did not. Furthermore, senescent VSMC conditioned media 
caused the IL-1α–dependent upregulation of the adhesion 
molecules vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1 (ICAM-1), and E-selectin 
in ECs (Figure 5C and 5D). This suggests that in addition to 
the direct release of inflammatory factors, senescent VSMCs 
can cause normal cells to release cytokines and upregulate 
adhesion molecules.
Senescent VSMCs Have a High Energy Demand 
That Allows Their Selective Elimination
The transcription, translation, processing, and secretion 
of multiple proteins at high concentration are an intrinsi-
cally energy-intensive process. Furthermore, such demand 
can lead to misfolded proteins triggering the unfolded pro-









































































































Figure 4. Senescent vascular smooth muscle cells (VSMCs) induce chemotaxis, secrete active matrix metalloproteinase-9 (MMP-9), 
and upregulate inflammasome components. A, Number of THP-1 cells migrating toward control or senescent VSMCs, ±neutralizing 
interleukin-1α (IL-1α), MCP-1, or IL-8 antibodies. B, Enumeration of immune cells recruited to the peritoneum of mice in response to 
control or senescent VSMCs. C, Gelatin gel zymography showing level and activity of MMPs in the conditioned media of control, IL-1α–
treated or senescent VSMCs. D, Amount of collagen produced by equal numbers of control or senescent VSMCs. E, Relative expression 
of transcripts for inflammasome-associated components in control or senescent VSMCs. Data represent mean±SEM of n=4 (A), 3 (B and 
D), 2 (E); *P≤0.05, **P≤0.02, ***P≤0.005. ND indicates not detected.
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whether the VSMC SASP necessitates metabolic alterations 
to meet such energy demands, we used a Seahorse extracel-
lular flux analyzer. Measurement of the extracellular acidifi-
cation rate indicated senescent cells to have glycolytic rates 
≈2.6-fold higher than control cells (Figure 6A), which was 
shown to be specific by abolishment with the glycolytic 
inhibitor 2-deoxyglucose (Figure 6A). Similarly, the oxy-
gen consumption rate indicated senescent VSMCs to use 
≈2-fold more oxidative phosphorylation than control cells 
(Figure 6B), with a higher basal, maximal, and spare respi-
ratory capacity. However, senescent VSMCs show no active 
unfolded protein response, as evidenced by a lack of spliced 
X-box binding protein 1 (XBP-1; Figure 6C). This indicates 
that senescent VSMCs adapt to a hypermetabolic and hyper-
biosynthetic state to enable the high-level protein production 
of the SASP without proteotoxic stress. Metabolic targeting 
is a developing potential anticancer therapy that relies on 
the altered metabolic requirements of tumor cells.23 Given 
the hypermetabolic state of senescent VSMCs, we investi-
gated whether a similar strategy could lead to their selective 
elimination. Treatment of VSMCs with 2-deoxyglucose (a 
glucose analog that competitively inhibits glycolysis) lead 
to significantly more death of senescent than control cells 
(Figure 6D and 6E). Dying cells showed features of apopto-
sis, such as pyknotic nuclear condensation and cellular bleb-
bing (Figure 6F). Together, these data suggest that the high 
energy demand of senescent VSMCs could enable metabolic 
targeting and potentially their selectively elimination.
Senescent Cells Within Human Carotid  
Plaques Express IL-1α and Colocalize 
With IL-6 and CD68
To assess whether these findings are of significance to ath-
erosclerosis in vivo, we examined SAβG-stained human 
carotid plaques. Senescent VSMC-like cells within the 
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Figure 5. Vascular smooth muscle cell (VSMC) senescence-associated secretory phenotypes (SASPs) can prime adjacent control cells to a 
proinflammatory state. A and B, Interleukin-6 (IL-6) and IL-8 content of cell lysates from control VSMCs (A) or human umbilical vein endo-
thelial cells (HUVECs; B) incubated with IL-1α or conditioned media (CM) from control or 2 senescent VSMC cultures, ±neutralizing IL-1α 
pAb. IL-8 values are scaled 2.5-fold lower. C, Flow cytometry plots showing IL-1α–dependent increase in surface E-selectin expression 
after treatment as indicated. D, Mean fluorescent intensities (MFIs) of adhesion molecules on HUVEC populations analyzed by flow cytometry 
after treatment as indicated, ±neutralizing IL-1α pAb (Ab). Data represent mean±SD of n=3 (A), 2 (B–D); **P≤0.02 and *** P≤0.005.
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with adjacent SAβG-negative cells (Figure 7A). As we 
have shown that the VSMC SASP induces cytokine expres-
sion in adjacent cells, we examined plaques for regions of 
SAβG-positive cells that had increased local IL-6 expres-
sion. SAβG-positive cells showed both IL-6 expression 
and increased IL-6 expression in adjacent cells (Figure 7B 
and 7C), including IL-6 expression in the overlying endo-
thelium (Figure 7C). Given that senescent VSMCs cause 
chemotaxis of mononuclear cells via MCP-1, we exam-
ined whether increased levels of CD68-positive cells were 
found in the vicinity of SAβG-positive cells. Large areas 
of the plaque could be seen to have increased levels of 
CD68-positive and SAβG-positive cells near to one another 
(Figure 7D), whereas other areas showed a focal accumula-
tion of both SAβG- and CD68-positive cells (Figure 7E). 
Together, these data suggest that senescent cells in human 
plaques express IL-1α that can drive increased local expres-
sion of inflammatory cytokines, causing attraction of mono-
nuclear cells.
Discussion
Atherosclerosis is a disease that develops over decades in 
humans. Although many atherogenic processes and epidemio-
logical risk factors are known, no evidence of causation exists 
in humans. Most agree that inflammation is a key initiator and 
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Figure 6. Senescent vascular smooth muscle cells (VSMCs) adopt a hypermetabolic state that enables their selective elimination. A and 
B, Measurement of glycolysis by the extracellular acidification rate (ECAR; A) and oxidative phosphorylation by the oxygen consumption 
rate (OCR; B) in control (gray) and senescent (black) VSMCs treated at times indicated with: I=oligomycin; II=FCCP; III=2-deoxyglucose 
(2-DG); and IV=rotenone/antimycin. C, Level of XBP-1 splicing in control and senescent VSMCs measured by qPCR (quantitative poly-
merase chain reaction) and RT-PCR (reverse transcription-polymerase chain reaction). D, Cell number measured by crystal violet follow-
ing treatment of control (gray) and senescent (black) VSMCs with 2-DG for 4 days. E, Propidium iodide staining reveals increased levels 
of cell death in senescent VSMCs after 2-DG treatment. F, Senescent VSMC treated with 2-DG displaying cellular blebbing, pyknotic 
nuclear condensation, and propidium iodide negativity indicative of apoptosis. Data represent mean±SD of n=2; *P≤0.05, **P≤0.02. Scale 
bars represent 50 mm.
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this and why it does not resolve is unclear. Senescent VSMCs 
are found in human plaques16 (Figure 1A) and are thought to 
contribute to the disease. However, they are observed to be 
rare and therefore how so few cells can have any functionally 
important effect is unclear. Furthermore, it is not known 
whether any effect of VSMC senescence is only through inac-
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Figure 7. Senescent cells in human carotid plaques express interleukin-1α (IL-1α) and colocalize with IL-6 and CD68. Human carotid 
endarterectomy samples stained for senescence-associated β-galactosidase (SABG): showing senescent vascular smooth muscle cell 
(VSMC)-like cells in the fibrous cap that coexpress IL-1α (A); a discrete region containing many senescent cells showing localized IL-6 
expression, in contrast to an adjacent region with no senescent cells or IL-6 (B); area within a fibrous cap (FC) showing high levels of local 
IL-6 expression adjacent to senescent cells (C); a large composite image showing localization between senescent and CD68 +ve cells 
(outlined and enlarged below; D); a region showing focal accumulation of senescent and CD68 +ve cells (E). Only eosin counterstain was 
used. Scale bars represent 100 and 25 mm (B; high power). L indicates lumen; and NC, necrotic core.
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We find that senescent human VSMCs may actively 
contribute to atherogenesis and plaque rupture through the 
establishment of a SASP. The SASP is characterized by the 
persistent release of multiple inflammatory cytokines and che-
mokines, which is driven by autocrine stimulation of senes-
cent VSMCs by IL-1α. These powerful chemotactic signals 
cause recruitment of monocytes and lymphocytes in vitro and 
in vivo, whereas secreted IL-1α activates adjacent normal 
VSMCs and ECs, resulting in the amplification of proinflam-
matory cytokine release and expression of adhesion receptors. 
Senescent VSMCs also secrete less collagen and more active 
MMP9 that can degrade collagen within the structural matrix, 
which could further weaken the plaque. This persistent high-
level expression of secreted proteins necessitates a hyper-
metabolic state sustained by increased levels of glycolysis and 
oxidative phosphorylation. This renders senescent VSMCs 
sensitive to metabolic targeting with glycolysis inhibitors that 
selectively kill them. Thus, senescent VSMCs are unappreci-
ated drivers of inflammation and matrix destruction in the ves-
sel wall that do not require external stimuli or infiltrating cells.
The predominant view on the role of senescent VSMCs 
in atherosclerosis is that of inaction—failure to proliferate 
results in a VSMC-poor and matrix-poor unstable fibrous cap. 
Although no longitudinal study on the frequency of senescent 
VSMCs with plaque maturity exists, they are observed to be 
rare cells. Therefore, how few cells could affect plaque biol-
ogy has been a puzzle. One possibility for this observed rarity 
is that senescent cells are cleared in vivo. However, without 
fragmentation, it is hard to rationalize how a phagocyte could 
engulf such a large cell. The data presented here indicate how 
small numbers of senescent VSMCs could have a much larger 
effect on plaque biology. First, once the SASP is established it 
is persistent and requires no external stimulation to maintain 
it. In vitro we have observed high-level secretion of cytokines/
chemokines from senescent VSMCs for over 6 weeks, with no 
significant cell loss over many months (Humphry and Clarke, 
unpublished data, 2014, and Figure VII in the online-only 
Data Supplement). In contrast, macrophages rapidly undergo 
desensitization to activating stimuli, resulting in abatement of 
inflammatory responses. Therefore, a SASP can act as a con-
stant source of inflammatory cytokines and chemokines for 
the life of the senescent VSMC within the plaque. Second, 
senescent VSMCs secrete IL-1α (the apical effector of the 
SASP) into the local milieu, as opposed to the typical cell sur-
face expression on other senescent cell types,9 expanding the 
range of any effect. Normal VSMCs and ECs are responsive 
to IL-1, which results in the production of more proinflamma-
tory cytokines and chemokines—effectively amplifying the 
signal. Indeed, control VSMCs treated with IL-1α, or media 
conditioned by senescent VSMCs, effectively phenocopy the 
SASP. Third, senescent VSMCs require no external stimula-
tion or interaction with infiltrating cell types to generate ves-
sel inflammation. Thus, small numbers of senescent VSMCs 
could theoretically seed inflammation throughout the vessel 
wall over extended time periods.
A key feature of atherogenesis is the constant recruitment 
of monocytes into the vessel wall and neointima. Several che-
mokines are components of the VSMC SASP, including MCP-
1, MIP-1α/CCL3, and MIP-1β/CCL4. MCP-1 is well known 
to drive monocyte recruitment and deletion in mice results in 
dramatic reduction in recruitment and plaque growth.24 Indeed, 
we find MCP-1 to be the main SASP component that drives 
mononuclear cell migration (Figure 4A). Similarly, CCL3 and 
CCL4 are powerful chemokines for monocyte/macrophages 
and lymphocytes, and genetic blockade of CCL3/4 signal-
ing decreases plaque size.25,26 However, CCL3 was originally 
identified as stem cell inhibitor, which inhibits proliferation 
of hemopoietic progenitors27 and other differentiated cells.28,29 
Interestingly, CCR5−/−/ApoE−/− mice (CCR5 is CCL3’s recep-
tor) have smaller plaques with an unexplained 3-fold increase 
in VSMCs,26 whereas bone marrow CCR5−/−does not affect 
plaque VSMC number.25 This suggests an inhibitory effect of 
CCR5 signaling on VSMC proliferation in vivo, and a poten-
tial cytostatic effect of the VSMC SASP. IL-6 and IL-8 are the 
principle SASP components and are found to be expressed by 
all senescent cell types.8 However, although IL-6 is power-
fully associated with risk of MI,30,31 its precise contribution to 
atherogenesis is unclear and controversial.32,33 IL-8 is primar-
ily a chemoattractant for neutrophils, but evidence suggests 
that it may promote firm adhesion of monocytes to ECs34 and 
cause their accumulation in plaques.35 In addition, IL-8 is an 
angiogenic factor that has been reported to induce angiogen-
esis in human coronary plaques,36 potentially driving growth 
of a pathological vasa vasorum. Together, the factors released 
by the VSMC SASP are highly likely to have a harmful impact 
on plaque growth and stability.
Identifying causation of in vitro findings in humans is 
hard. In addition, although atherosclerosis can be modeled in 
mice, VSMCs do not undergo senescence in these systems and 
establishment of SASPs in mouse cells is atypical.37 Human 
plaque VSMCs undergo telomere shortening-based senes-
cence that is accelerated by DNA damage.16 Therefore, the 
lack of VSMC senescence in mice maybe because of their 
extremely long telomeres that delay senescence beyond the 
time frame of atherosclerosis experiments, and indeed mouse 
lifespan. Therefore, establishing direct consequences of 
VSMC senescence and the SASP in vivo is difficult. However, 
by examining SAβG-stained human carotid plaques, we have 
revealed senescent VSMC-like cells to express increased lev-
els of the SASP-driver IL-1α. In addition, increased levels 
of IL-6 are found in SAβG-positive cells and adjacent nor-
mal cells, suggesting that the SASP can indeed activate other 
nearby cells to amplify inflammation. Finally, we find a sig-
nificant relationship between SAβG cells and local accumula-
tion of CD68-positive mononuclear cells, implying senescent 
cells can indeed drive chemotaxis in vivo.
Because of the multiplicity of risk factors, biological pro-
cesses and cell types involved in atherosclerosis, therapeutic 
targeting to reduce growth or stabilize plaques is a challenging 
task. However, inflammation is well accepted to play a key 
role at all stages of atherogenesis from the early recruitment 
of monocytes that form fatty streaks through to final rupture. 
Because of this, and evidence for cholesterol crystal-activated 
inflammasomes producing IL-1β, the Canakinumab Anti-
inflammatory Thrombosis Outcomes Study (CANTOS) was 
instigated. This study is the first to test whether blocking an 
inflammatory pathway in humans can reduce cardiovascular 
events. However, Canakinumab is a humanized monoclonal 
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antibody specific for IL-1β, thus leaving the action of IL-1α 
completely unopposed. In many cases, IL-1β and IL-1α are 
cosecreted,17,18 whereas other atherosclerosis models show 
exclusive release of and dependence on IL-1α.19 Herein, we 
present data for another potentially important source of inflam-
mation within the vessel wall that is also exclusively driven 
by IL-1α (Figure 2C–2F). Indeed, if a significant aspect of 
inflammation in atherosclerosis is driven by IL-1α, the effects 
in CANTOS may not seem as efficacious as required, or at 
worse the trial may fail losing a real therapeutic opportunity.
With every life lost to cardiovascular disease, the pressure 
to develop new treatment strategies and therapeutics builds. 
However, to achieve this, a detailed understanding of the 
precise mechanisms and processes underlying the disease is 
needed. We show that senescent VSMCs establish an inflam-
matory SASP driven by IL-1α that may have multiple nega-
tive effects on atherosclerosis. Although small numbers of 
senescent VSMCs are reported in plaques, secreted IL-1α can 
act on other normal vessel wall cells, inducing them to pro-
duce proinflammatory cytokines and to upregulate adhesion 
molecules, effectively amplifying the effect. We think senes-
cent VSMCs may play an as yet unreported role in driving 
inflammation during atherosclerosis.
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Atherosclerotic plaques are the primary cause of ischemic heart disease and stroke—the leading causes of death. Plaque formation involves 
infiltration of myeloid cells into the vessel wall, proliferation, and migration of vascular smooth muscle cells (VSMCs) out into the forming 
plaque and interaction between these cell types. Inflammation is a key driver of the disease. However, overproliferation and DNA damage 
cause VSMCs to undergo senescence. Because VSMCs maintain plaques in an asymptomatic stable phenotype senescence is thought to 
contribute to the disease process by inaction. In contrast, we show that senescent VSMCs perpetually secrete multiple cytokines that drive 
inflammation and myeloid cell recruitment. This is driven by secreted interleukin-1α acting in an autocrine manner, which can also activate 
adjacent VSMCs and endothelial cells, amplifying the effect. This work contests the paradigm that senescent VSMCs are inactive bystand-
ers in vascular disease, and that a potentially important source of inflammation requires blockade of interleukin-1α and not interleukin-1β.
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